Seed Therapeutics Inc. has gained IND clearance from the U.S. FDA for ST-01156, a brain-penetrant RBM39 degrader. The clearance enables initiation of a first-in-human phase I trial in patients with advanced solid tumors and hematological malignancies, prioritizing biomarker-selected RBM39-dependent cancers. Dosing is expected to begin in the first quarter of next year.
Primelink Biotherapeutics (Shenzhen) Co. Ltd. has discovered molecular glue degraders acting as eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) degradation inducers reported to be useful for the treatment of cancer.
Discoidin domain receptor tyrosine kinase 1 (DDR1) contributes to tumor progression by promoting the alignment and densification of collagen fibers within the extracellular matrix (ECM), thereby facilitating the development of an immune-excluded tumor microenvironment (TME).
Polycystic ovary syndrome is a common endocrine disorder in women of reproductive age and characterized by obesity, insulin resistance and renal injury.
Dana Farber Cancer Institute Inc. and Stanford University have patented new molecular glue degraders comprising cereblon (CRBN) binding moiety acting as casein kinase 1 isoform α and/or wee1-like protein kinase (Wee1) degradation inducers reported to be useful for the treatment of cancer.
Amphista Therapeutics Ltd. has identified compounds acting as bromodomain-containing protein 9 (BRD9) degradation inducers reported to be useful for the treatment of cancer.
Nanjing Chia Tai Tianqing Pharmaceutical Co. Ltd. has disclosed bifunctional compounds acting as RAC serine/threonine-protein kinase (AKT; PKB) degraders reported to be useful for the treatment of cancer.
Astrazeneca AB has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune diseases and respiratory disorders.
RSS
